Scientific work

Arcana Institute actively publishes outcomes of the conducted research 

1. EPROSARTAN VERSUS OTHER ANGIOTENSIN – RECEPTOR BLOCKERS COMMONLY USED IN POLAND (IRBESARTAN, LOSARTAN, TELMISARTAN AND VALSARTAN) IN PATIENTSWITH HYPERTENSION – DIRECT COMPARISON 
2. EPROSARTAN VERSUS OTHER ANGIOTENSIN – RECEPTOR BLOCKERS COMMONLY USED IN POLAND IN PATIENTSWITHHYPERTENSION – INDIRECT COMPARISON 
3. THE NATIONAL HEALTH FOUND BUDGET IMPACT ANALYSIS OF INFUENZA VACCINATION REIMBURSEMENT IN CHILDREN WITH MALIGNANCIES IN POLAND 
4. COST EFFETIVENESS OF AMISULPRID IN THE TREATMENT OF SCHIZOPHRENIA 
5. THE BUDGET IMPACT OF APIDRA® (INSULIN GLULISINE) REIMBURSEMENT IN POLAND 
6. THE COST-EFFECTIVENESS OF INSULIN GLULISINE IN TYPE 2 DIABETES IN POLAND 
7. BUDGET IMPACT ANALYSIS OF THE CONTINUATION OF DOCETAXEL REIMBURSEMENT IN THE NEOADJUVANT THERAPY OF LOCALLY ADVANCED BREAST CANCER AND PALLIATIVE THERAPY OF METASTATIC BREAST CANCER IN POLAND 
8. COST-UTILITY ANALYSIS OF DOCETAXEL VERSUS STANDARD REGIMEN IN THE NEOADJUVANT THERAPY OF LOCALLY ADVANCED BREAST CANCER IN POLAND 
9. THE COST-UTILITY AND BUDGET IMPACT ANALYSIS OF SITAGLIPTIN JANUVIA IN TYPE 2 DIABETES IN POLAND 
10. COMPARATIVE COST-UTILITY ANALYSIS OF LONG-ACTING INSULIN ANALOGUE (INSULIN DETEMIR) AND NPH INSULIN FOR THE TREATMENT OF TYPE 1 AND TYPE 2 DIABETES AND THE BUDGET IMPACT ANALYSIS OF INSULIN ANALOGUE REIMBURSEMENT IN POLAND
11. COST-UTILITY AND BUDGET IMPACT OF SERTINDOLE IN THE TREATMENTOF SCHIZOPHRENIA IN POLAND
12. Systematic review of the efficacy and safety of imiquimod 5% cream for the treatment of superficial basal cell carcinoma.
13. Cost-effectiveness analysis of imiquimod (Aldara®) versus no treatment in patients with superficial basal cell carcinoma and contraindication to surgical intervention/cryotherapy
14. Cost-effectiveness analysis of imiquimod (Aldara®) versus no active treatment in actinic keratoses 
15. Cost-effectiveness analysis of imiquimod (Aldara®) versus podophyllotoxin in treatment of genital/perianal warts in Poland 
16. Systematic review of the efficacy and safety of imiquimod 5% cream for the treatment of actinic keratoses 
17. Systematic review of the efficacy and safety of imiquimod 5% cream for the treatment of external genital warts 
18. THE COST-EFFECTIVENESS ANALYSIS OF VIDALGLIPTIN IN TYPE 2 DIABETES IN POLAND
19. THE BUDGET IMPACT ANALYSIS OF VILDAGLIPTIN IN TYPE 2 DIABETES IN POLAND
20. THE COST-EFFECTIVENESS ANALYSIS OF VARENICLINE FOR SMOKING CESSATION IN POLAND
21. SYSTEMATIC REVIEW OF THE EFFICACY AND SAFETY OF VARENICLINE FOR SMOKING CESSATION COMPARED WITH PLACEBO, NICOTINE REPLACEMENT THERAPY OR SUSTAINED-RELEASE BUPROPION
22. SYSTEMATIC REVIEW OF THE EFFICACY AND SAFETY OF VILDAGLIPTIN FOR TYPE 2 DIABETES MELLITUS
23. COMPARATIVE ANALYSIS OF THE EFFICACY AND SAFETY OF ESCITALOPRAM WITH SERTRALINE AND VENLAFAXINE IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
24. ESCITALOPRAM (GENERIC DRUG) IN MAJOR DEPRESSIVE DISORDER (MDD) – BUDGET IMPACT ANALYSIS
25. ECONOMIC ANALYSIS OF ESCITALOPRAM (GENERIC DRUG) IN MAJOR DEPRESSIVE DISORDER (MDD)
26. ECONOMIC ANALYSIS OF ENOXAPARIN IN COMPARISON WITH FONDAPARINUX IN THE TREATMENT OF DEEP-VEIN THROMBOSIS (DVT)